Phase 1/2 Study Examines MB-106 in Various Positive B-cell Malignancies

Partners | <b>Fred Hutch Cancer Center</b>

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

According to Shadman, there is an unmet need for more CAR T products that can be used to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). As a result, the CD20 directed CAR T-cell therapy, MB-106, is being examined in this ongoing trial to further understand its safety and efficacy.

This phase 1/2 study is examining the CAR T product in patients with positive B-cell malignancies, including relapsed/refractory B-NHL, follicular lymphoma, Waldenstrom, and CLL with the goal of finding it to have an acceptable safety and toxicity profile.

Transcription

0:08 | We reported the updated results of our ongoing phase 1/2 clinical trial using a CD20 directed CAR T product. This is a third generation CAR with both a CD20 and 4-1BB costimulatory molecule. We have treated 25 patients so far, and that's what we presented at the TCT meeting. A majority of our patients have follicular lymphoma, 18 out of 25, but we have patients with CLL, patients with diffuse large B-cell lymphoma, and Waldenstrom. We reported the safety and efficacy of this treatment in patients that we've treated so far.

0:50 | I also would like to add that for this presentation, for the first time, we were reporting on patients who had a prior treatment with CD19 CAR. As we think about the implications and indications of new CAR T products for the current treatment landscape, the post CD19 CAR space is clearly a clinical unmet need and area. We're excited to see responses about patients that we wish to be treated in that setting, and for the safety profile in lymphoma in general, low grade lymphomas, follicular lymphoma and CLL. It is extremely important that the product has a very acceptable safety and toxicity profile.